Kairos Pharma Ltd.
KAPA | AMEX
$1.75
+$0.02 (+1.16%)
At close: Sep 21, 2026, 3:59 PM ET
$1.77
+$0.02 (+1.14%)
Pre-market:
Sep 22, 2026, 8:36 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 160K | 160K | 160K | 98K | n/a |
Gross Profit | n/a | -160K | -160K | -160K | -98K | n/a |
Operating Income | -5.57M | -2.34M | -1.71M | -571K | -1.94M | -1.05M |
Interest Income | 125K | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -5.45M | -2.6M | -1.81M | -1.05M | -2.15M | -1.05M |
Net Income | -5.45M | -2.6M | -1.81M | -1.05M | -2.15M | -1.05M |
Selling & General & Admin | 3.44M | 1.77M | 1.47M | 324K | 1.66M | 1.03M |
Research & Development | 2.14M | 414K | 82K | 87K | 183K | 20K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 5.57M | 2.18M | 1.55M | 411K | 1.85M | 1.05M |
Interest Expense | n/a | 859K | 98K | 479K | 202K | 5.41K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 5.57M | 2.34M | 1.71M | 571K | 1.94M | 1.05M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 2.63M | 1.62M | 1.48M | 1.46M | 1.83M | 1.6M |
Shares Outstanding (Diluted) | 2.63M | 1.62M | 1.48M | 1.46M | 1.83M | 1.6M |
EPS (Basic) | -2.10 | -1.61 | -1.19 | -0.70 | -1.19 | -0.66 |
EPS (Diluted) | -2.10 | -1.61 | -1.19 | -0.70 | -1.19 | -0.66 |
EBITDA | -5.29M | -1.58M | -1.55M | -411K | -1.85M | -1.05M |
EBIT | -5.45M | -1.74M | -1.71M | -571K | -1.94M | -1.05M |
Depreciation & Amortization | 160K | 160K | 160K | 160K | 98K | n/a |
Add to Watchlist
Select watchlists to add or remove KAPA